TABLE 2

HPV Vaccine Coverage Among Patients Aged 11 or 12 Years, 3- and 6-Month Posttraining (n = 17 173).

3-Months Posttraining6-Months Posttraining
Coverage at 3 Mo (%)aCoverage Change Over Previous 3 Mo (%)bDifference From Control (%) (95% CI)bPCoverage at 6 Mo (%)aCoverage Change Over Previous 6 Mo (%)bDifference From Control (%) (95% CI)bP
≥1 dose
 Control37.36.4Reference41.29.5Reference
 Announcement38.011.55.1 (2.0 to 8.2).003*42.014.95.4 (1.1 to 9.7).02*
 Conversation30.38.42.0 (–0.4 to 4.4).1033.711.52.0 (–1.4 to 5.5).24
≥1 dose to girls
 Control39.67.2Reference44.011.2Reference
 Announcement41.012.04.8 (1.6 to 8.0).004*45.215.74.6 (0.1 to 9.0).045*
 Conversation33.08.81.5 (–0.9 to 4.0).2136.411.90.7 (–2.9 to 4.3).69
≥1 dose, boys
 Control35.76.0Reference39.28.4Reference
 Announcement35.811.65.6 (2.0 to 9.1).003*39.714.76.2 (1.5 to 11.0).01*
 Conversation28.38.12.1 (–0.5 to 4.8).1131.911.32.8 (–0.9 to 6.6).13
3 doses
 Control11.51.9Reference13.53.6Reference
 Announcement9.22.60.7 (–0.7 to 2.1).3210.73.90.3 (–1.8 to 2.3).81
 Conversation7.21.5−0.4 (–1.4 to 0.7).489.23.3−0.3 (–2.1 to 1.5).71
3 doses, girls
 Control12.62.1Reference14.74.0Reference
 Announcement11.13.00.9 (–0.5 to 2.4).2112.94.30.3 (–1.9 to 2.4).81
 Conversation8.92.00.0 (–1.1 to 1.1).9711.04.00.0 (–2.0 to 1.9).97
3 doses, boys
 Control10.61.8Reference12.53.3Reference
 Announcement7.52.10.3 (–1.3 to 1.8).708.83.40.1 (–2.3 to 2.4).96
 Conversation5.91.2−0.6 (–1.8 to 0.6).287.62.7−0.6 (–2.6 to 1.4).55
  • a Vaccine coverage is unadjusted.

  • b Three- and 6-month coverage change and comparisons among trial arms are adjusted for clustering at the clinic level.

  • * P < .05.